What is the recommended treatment for influenza, including antiviral therapy, dosing adjustments for renal impairment, pediatric dosing, and supportive care?

Flu Treatment

For influenza treatment, oseltamivir 75 mg twice daily for 5 days is the first-line antiviral for adults and weight-based dosing for children, initiated ideally within 48 hours of symptom onset, with dose adjustments required for renal impairment (creatinine clearance 10-30 mL/min: 75 mg once daily). 1

Antiviral Therapy

Adults

• Oseltamivir: 75 mg orally twice daily for 5 days 1, 2
• Zanamivir: 10 mg (two 5-mg inhalations) twice daily for 5 days 1
• Baloxavir: Single dose based on weight (40 mg for 40-80 kg; 80 mg for ≥80 kg) 1
• Peramivir: 600 mg IV infusion over 15-30 minutes (single dose) 1

Pediatric Dosing (Oseltamivir)

Children ≥12 months (weight-based):

• <15 kg: 30 mg twice daily
• 15-23 kg: 45 mg twice daily
• 23-40 kg: 60 mg twice daily

• 40 kg: 75 mg twice daily 1

Infants 9-11 months: 3.5 mg/kg/dose twice daily 3

Term infants 3-8 months: 3 mg/kg/dose twice daily 1

Infants 0-3 months: 3 mg/kg/dose twice daily (treatment only; limited safety data) 4

Preterm infants (by postmenstrual age):

• <38 weeks: 1.0 mg/kg/dose twice daily
• 38-40 weeks: 1.5 mg/kg/dose twice daily

• 40 weeks: 3.0 mg/kg/dose twice daily 3

Renal Impairment Adjustments

For creatinine clearance 10-30 mL/min:

• Treatment: 75 mg once daily for 5 days
• Prophylaxis: 30 mg once daily OR 75 mg every other day for 10 days 5

Renal dosing tables from CDC may be useful for pediatric patients qualifying for adult doses (>40 kg) 1.

Timing and Indications

Critical timing consideration: Antiviral therapy provides maximum benefit when initiated within 48 hours of symptom onset, reducing illness duration by approximately 24 hours 6. However, treatment should still be considered for hospitalized patients or those with severe/progressive disease even beyond 48 hours 1.

Treat empirically when:

• Influenza is circulating in the community AND patient has influenza-like illness (fever >38°C in adults, >38.5°C in children, plus respiratory symptoms) 6
• Confirmed influenza infection
• Severe illness or high-risk patients regardless of symptom duration

High-Risk Groups Requiring Treatment

• Hospitalized patients
• Severe or progressive illness
• Children <2 years (especially <6 months)
• Adults ≥65 years
• Pregnant or postpartum women (within 2 weeks of delivery)
• Chronic medical conditions (pulmonary, cardiac, renal, hepatic, neurologic, hematologic, metabolic disorders including diabetes)
• Immunocompromised patients
• Morbid obesity (BMI ≥40) 1

Alternative Antivirals

Zanamivir (inhaled dry powder):

• Approved for children ≥7 years (treatment) and ≥5 years (prophylaxis)
• 10 mg (two 5-mg inhalations) twice daily for 5 days
• Contraindicated in chronic respiratory diseases (asthma, COPD) due to bronchospasm risk 5
• Not administered via nebulizer or ventilator 4

Baloxavir (single-dose oral):

• Approved for patients ≥5 years and ≥20 kg
• Superior viral load reduction compared to oseltamivir but comparable symptom relief 7
• Resistance variants can emerge 7

Formulation Details

Oseltamivir is available as:

• Capsules: 30 mg, 45 mg, 75 mg
• Oral suspension: 6 mg/mL concentration (reconstituted powder)
• Can be administered without regard to meals, though food may improve GI tolerability 1

If commercial suspension unavailable, capsules can be opened and mixed with sweetened liquid, or pharmacies can compound suspension (6 mg/mL final concentration) 5.

Prophylaxis Dosing

Post-exposure prophylaxis (within 48 hours of exposure):

• Adults: Oseltamivir 75 mg once daily for 7-10 days 1
• Children: Same weight-based doses as treatment, but once daily 1
• Duration: 7 days after last exposure (minimum 14 days for institutional outbreaks) 1

Common Pitfalls

Avoid these errors:

• Delaying treatment beyond 48 hours in high-risk patients—still treat if severe illness present
• Using zanamivir in patients with asthma/COPD
• Forgetting renal dose adjustments—can lead to toxicity
• Underdosing preterm infants or using term infant doses (causes excessive drug concentrations) 4
• Using amantadine/rimantadine—high resistance rates make these obsolete 8

Adverse Effects

Oseltamivir: Nausea (~10%), vomiting, diarrhea; rare neuropsychiatric events and bleeding 9

Management: Administer with food for GI symptoms; consider mild antiemetics 6

Adjunctive Therapies

NOT recommended:

• Antibiotics (unless bacterial co-infection confirmed) 10
• Corticosteroids (associated with increased mortality) 11, 10
• NSAIDs, macrolides, mTOR inhibitors 10

Supportive care includes:

• Antipyretics for fever/discomfort
• Adequate hydration
• Respiratory support as needed for severe cases

Resistance Considerations

Current surveillance shows most influenza strains remain sensitive to oseltamivir and zanamivir, with <2% resistance to oseltamivir among H1N1 viruses 8. Continuous monitoring of local resistance patterns is essential. If resistance is suspected or confirmed, zanamivir or baloxavir are alternatives 8.